Acer Therapeutics (NASDAQ:ACER) announces that the FDA has accepted for review Acer’s NDA for EDSIVO for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
The FDA also granted a priority review of the NDA and assigned a PDUFA target action date of June 25, 2019.
Priority Review shortens the review clock to six months from the standard 10 months.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.